Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).
The drug, Gavreto, is an oral therapy which selectively targets so-called RET-altered cancers that have mutations that drive tumor growth, which are detected by a test approved by the U.S. Food and Drug Administration.
Swiss drugmaker Roche in July struck a pact worth up to $1.7 billion with Blueprint Medicines, for rights to Gavreto, which also awaits FDA approval for treating advanced RET mutant and RET fusion-positive thyroid cancers.
Simulation driven Cost & Time Reduction for Vaccine and API Manufacturing
10 September 2020 @ 10:30 AM
Pharma Manufacturing systems are highly variable with each system having different levels of interdependence and variability. These factors increase the unpredictability of the system making it increasingly difficult to predict the behavior. Learn how sim
The drug will be jointly marketed in the United States and will be available within a week, Blueprint said.
Only about 1-2% of patients with NSCLC have RET fusions, according to Roche.